ROIV News and Press, Roivant Sciences Ltd. From 05/29/24

2024-05-29 10:50:14 ET Major earnings expected before the bell on Thursday include: Best Buy ( BBY ) Canopy Growth ( CGC ) Dollar General ( DG ) Hormel Foods ( HRL ) Royal Bank of Canada ( RY ) Read the full article on Seeking Alpha Fo...

BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31...

2024-05-01 10:47:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding firms with strong growth potential is essential for healthcare investors looking for large profits. Three exceptional firms have surfaced as strong healthcare stocks . Each exhibits...

2024-04-25 10:05:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0% since inception, compa...

2024-04-24 15:15:35 ET Summary Roivant Sciences sold a subsidiary for $7.1 billion and plans a $1.5 billion stock buyback. Its pipeline includes promising drugs like IMVT-1402, despite some clinical risks. Financially, Roivant is well-capitalized with $6.67 billion in cash aga...

2024-04-24 07:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-14 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-10 04:22:17 ET Summary Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna. The ruling opens the way for a potential total win against Moderna, but uncertainties remain regarding the lawsuit and Arbutu...

2024-04-03 12:27:33 ET More on Arbutus Biopharma Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M Arbutus Biopharma gains after Markman hearing on Thursday in...

2024-04-02 17:15:03 ET Goldman Sachs analyst issues BUY recommendation for ROIV on April 2, 2024 03:55PM ET. The previous analyst recommendation was Buy. ROIV was trading at $10.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...